CD34+, CD117+, HLA-DR+, CD13+, CD33+, CD38+, CD45-, CD11b-, CD10-, CD19-, CD4-, CD56- and CD3-.

GTW

46,XX,idic(7)(q11.2)[9]/46,XX[24]

FIGURE 1: Partial Karyotype showing idic(7) on the right.

TECHNICS: FISH with probe CEP 7 (D7Z1) SpectrumGreen (Vysis). Abbott Molecular, Des Planes, IL, USA.

RESULTS: The idic(7) shows a significant increase signal respect to the normal chromosome7.

FIGURE 2: FISH of a metaphase spread with CEP 7. A. The idic(7) shows a significant increase signal respect to the

normal chromosome7. B. Reverse DAPI image of the same metaphase.

First line treatment with azacitidine. The patient did not achieve complete remission. Hence she received a second line therapy with cytarabine and daunorubicin. After 7/3 protocol the complete achieved remision was obtained. The patient received  allogenic transplant and after it, she remains in complete remission.

To our knowledge 5 cases of idic(7)(q11.2) have been reported in the literature (Beverstock et al., 1996¹; Johansson et al., 2001²; Persad et al., 2012 https://doi.org/10.4267/2042/47541) All of them were described in adults ranging in age from 66 to 82 years, with acute myeloid leukemia and different subtypes FAB phenotype (M1, M2 and M4). At diagnosis, no additional cytogenetic anomalies were reported. The patients responded favorably to induction chemotherapy.

The present case had AML secondary to MDS syndrome and did not achieve complete remission after induction chemotherapy. The patient underwent a bone marrow transplantation and after 3 years she remains in complete remission.